Physician profile
James A Boyd
NPI 1629073929
$19,586.08
in general payments reported to CMS, 2019-2025
67 companies · $2,976 in 2025
The $2,976 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,254 · 2020: $2,381 · 2021: $3,275 · 2022: $2,913 · 2023: $2,690 · 2024: $2,096 · 2025: $2,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,762.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,495.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,027.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,674.46 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $1,600.92 | 2019-2025 | Ubrelvy, Synthroid, Qulipta |
| Lilly USA, LLC | $1,484.59 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $1,122.14 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $847.79 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $665.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $659.56 | 2019-2025 | Otezla, Repatha, Repatha |
| Antares Pharma, INC. | $584.62 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Amneal Pharmaceuticals LLC | $432.41 | 2019-2025 | Unithroid, Crexont |
| Pfizer INC. | $365.33 | 2019-2025 | |
| Corium, LLC | $341.73 | 2022-2025 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $337.94 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $337.37 | 2019-2025 | Capvaxive, Lagevrio, Gardasil 9 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.